Alzheimer's disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide. The onset of AD is characterized by mild memory difficulties, which progressively evolve into cognitive impairments, dysfunctions in complex daily activities, and other aspects of cognition. Unfortunately, by the time AD is clinically diagnosed, significant neuronal loss and neuropathologic lesions have already occurred in many brain regions. Therefore, timely drug delivery of neuroprotective medications before the onset of mild symptoms plays a crucial role in preventing potential damages. Although current diagnostic methods for AD have their limitations, researchers are making significant strides towards developing more effective screening methods. While invasive, expensive, and not widely available methods have been used in the past, researchers are now exploring alternative approaches that are rapid, efficient, and cost-effective. A promising approach is the use of multiplexed assays that can detect multiple AD-related biomarkers in a single blood sample. This advancement in technology has the potential to revolutionize early screening for AD and make it more accessible to those in need. Another approach is to use emerging technologies such as microfluidics, nanotechnology, and biosensors, which can improve the sensitivity and specificity of the detection process. These technologies hold promise for the development of rapid, accurate, and cost-effective AD screening tests. However, the current mainstream and conventional tests such as enzyme-linked immunosorbent assay (ELISA) cannot satisfy the AD biomarker detections due to their insufficient sensitivity . Despite significant progress made in the ultrasensitive detection of plasma Aβ levels through new antibody-based technologies like single-molecule arrays and immunoprecipitation mass spectrometry (IP-MS), their use for screening tests is limited due to their bulky, expensive, and time-consuming nature . On the other hand, next-generation biosensing techniques that use nanomaterial-based field-effect transistors (FETs) have shown promise for high-sensitivity and high-integration label-free biosensing. FETs offer a promising alternative for ultrasensitive detection. Recent advancements in semiconducting carbon nanotube (CNT) network films have demonstrated the potential for constructing highly sensitive FET biosensors, with the added benefit of batch-fabrication for low-cost production .